

## P.ENT COOPERATION TREATY

From the INTERNATIONAL BUREAU

PCT

NOTIFICATION OF ELECTION  
(PCT Rule 61.2)

To:

Assistant Commissioner for Patents  
 United States Patent and Trademark  
 Office  
 Box PCT  
 Washington, D.C.20231  
 ETATS-UNIS D'AMERIQUE

Date of mailing (day/month/year)  
 28 July 2000 (28.07.00)

in its capacity as elected Office

International application No.  
 PCT/JP99/06943

Applicant's or agent's file reference  
 PWO-19119

International filing date (day/month/year)  
 10 December 1999 (10.12.99)

Priority date (day/month/year)  
 14 December 1998 (14.12.98)

## Applicant

TAKE, Kazuhiko et al

1. The designated Office is hereby notified of its election made:

in the demand filed with the International Preliminary Examining Authority on:

31 May 2000 (31.05.00)

in a notice effecting later election filed with the International Bureau on:

2. The election  was

was not

made before the expiration of 19 months from the priority date or, where Rule 32 applies, within the time limit under Rule 32.2(b).


The International Bureau of WIPO  
 34, chemin des Colombettes  
 1211 Geneva 20, Switzerland

Facsimile No.: (41-22) 740.14.35

Authorized officer

Maria Kirchner

Telephone No.: (41-22) 338.83.38



**INTERNATIONAL PRELIMINARY EXAMINATION REPORT**  
**(PCT Article 36 and Rule 70)**

Applicant's or agent's file reference <b>PWO-19119</b>	<b>FOR FURTHER ACTION</b>	See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)
International application No. <b>PCT/JP99/06943</b>	International filing date ( <i>day/month/year</i> ) <b>10/12/1999</b>	Priority date ( <i>day/month/year</i> ) <b>14/12/1998</b>
International Patent Classification (IPC) or national classification and IPC <b>C07D413/06</b>		
<p>Applicant <b>FUJISAWA PHARMACEUTICAL CO., LTD. et al.</b></p> <p>1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.</p> <p>2. This REPORT consists of a total of 6 sheets, including this cover sheet.</p> <p><input type="checkbox"/> This report is also accompanied by ANNEXES, i.e. sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).</p> <p>These annexes consist of a total of sheets.</p> <p>3. This report contains indications relating to the following items:</p> <ul style="list-style-type: none"> <li>I <input checked="" type="checkbox"/> Basis of the report</li> <li>II <input type="checkbox"/> Priority</li> <li>III <input checked="" type="checkbox"/> Non-establishment of opinion with regard to novelty, inventive step and industrial applicability</li> <li>IV <input type="checkbox"/> Lack of unity of invention</li> <li>V <input checked="" type="checkbox"/> Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement</li> <li>VI <input checked="" type="checkbox"/> Certain documents cited</li> <li>VII <input type="checkbox"/> Certain defects in the international application</li> <li>VIII <input checked="" type="checkbox"/> Certain observations on the international application</li> </ul>		

Date of submission of the demand <b>31/05/2000</b>	Date of completion of this report <b>01.03.2001</b>
Name and mailing address of the international preliminary examining authority:  <b>European Patent Office D-80298 Munich Tel. +49 89 2399 - 0 Tx: 523656 epmu d Fax: +49 89 2399 - 4465</b>	Authorized officer <b>Goss, I</b> Telephone No. +49 89 2399 8292



# INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No. PCT/JP99/06943

## I. Basis of the report

1. This report has been drawn on the basis of (substitute sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to the report since they do not contain amendments (Rules 70.16 and 70.17).):

**Description, pages:**

1-231 as originally filed

**Claims, No.:**

1-10 as originally filed

2. With regard to the **language**, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.

These elements were available or furnished to this Authority in the following language: , which is:

- the language of a translation furnished for the purposes of the international search (under Rule 23.1(b)).
- the language of publication of the international application (under Rule 48.3(b)).
- the language of a translation furnished for the purposes of international preliminary examination (under Rule 55.2 and/or 55.3).

3. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international preliminary examination was carried out on the basis of the sequence listing:

- contained in the international application in written form.
- filed together with the international application in computer readable form.
- furnished subsequently to this Authority in written form.
- furnished subsequently to this Authority in computer readable form.
- The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.
- The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.

4. The amendments have resulted in the cancellation of:

- the description, pages:
- the claims, Nos.:
- the drawings, sheets:

5.  This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed (Rule 70.2(c)):

# INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No. PCT/JP99/06943

*(Any replacement sheet containing such amendments must be referred to under item 1 and annexed to this report.)*

## 6. Additional observations, if necessary:

### III. Non-establishment of opinion with regard to novelty, inventive step and industrial applicability

1. The questions whether the claimed invention appears to be novel, to involve an inventive step (to be non-obvious), or to be industrially applicable have not been examined in respect of:
  - the entire international application.
  - claims Nos. 8.

because:

- the said international application, or the said claims Nos. 8 relate to the following subject matter which does not require an international preliminary examination (*specify*):  
**see separate sheet**
- the description, claims or drawings (*indicate particular elements below*) or said claims Nos. are so unclear that no meaningful opinion could be formed (*specify*):
- the claims, or said claims Nos. are so inadequately supported by the description that no meaningful opinion could be formed.
- no international search report has been established for the said claims Nos. .

2. A meaningful international preliminary examination report cannot be carried out due to the failure of the nucleotide and/or amino acid sequence listing to comply with the standard provided for in Annex C of the Administrative Instructions:
  - the written form has not been furnished or does not comply with the standard.
  - the computer readable form has not been furnished or does not comply with the standard.

### V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

#### 1. Statement

Novelty (N)	Yes: Claims 4
	No: Claims 1-3,5-10
Inventive step (IS)	Yes: Claims
	No: Claims 1-10
Industrial applicability (IA)	Yes: Claims 1-9,10

**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT**

International application No. PCT/JP99/06943

No: Claims 8

2. Citations and explanations  
**see separate sheet**

**VI. Certain documents cited**

1. Certain published documents (Rule 70.10)

and / or

2. Non-written disclosures (Rule 70.9)

**see separate sheet**

**VIII. Certain observations on the international application**

The following observations on the clarity of the claims, description, and drawings or on the question whether the claims are fully supported by the description, are made:

**see separate sheet**

**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT - SEPARATE SHEET**

---

International application No. PCT/JP99/06943

**Priority**

The priority document pertaining to the present application has not been checked at the time of establishing this preliminary examination report. Hence, it is based on the assumption that all claims enjoy priority rights from the filing date of the priority document. If it later turns out that this is not correct, the document WO 98 57954 cited in the international search report could become relevant to assess whether claim 1 (and dependent claims thereon) satisfies the criteria set forth in Article 33(1) PCT.

**Novelty**

D2: WO 97 22597 describes compounds which do not fall within the scope of the subject-matter claimed mainly in view of the proviso introduced at the end of claim 1. However, it should be pointed out that the novelty of an invention whose subject-matter is a choice among a known group depends on whether the choice adduces a teaching of a technical nature not contained in the state of the art. The Examiner could not find wherein the structural distinction between D2 and the claimed subject-matter exactly resides.

Novelty cannot be recognized.

**Inventive step**

The problem underlying the present application appears to reside in the provision of further piperazine derivatives which have pharmacological activities such as Tachykinin antagonism.

D2 as well as D3: WO 97 08166 A both describe structurally very closely related compounds (see also under novelty) also useful as Tachykinin antagonists or more specifically neurokinin antagonists (D3). Data are given on pages 28 to 31 and 49 to 55 respectively.

The solution of the problem underlying the present application has to be seen in the provision of the derivatives according to claim 1 which, however, do not show any particular novelty rendering feature and for which no quantitative data could be found.

It appears that the problem as stated above has been already solved by the compounds claimed in D2.

Therefore in view of this objection above, the compounds claimed do not represent a solution to the problem stated supra since no unexpected effects or advantages which were not derivable from the teaching of the highly relevant document D2 were shown.

**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT - SEPARATE SHEET**

International application No. PCT/JP99/06943

Always in the case of a selection invention, the structural distinguishing portion must be responsible for the unforeseeable effects on which an inventive step could be recognized.

No inventive step can be acknowledged.

**Clarity**

The term "aryl further substituted" used in claim 1, is considered to be non-limitative and embraces an infinite number of possibilities not yet explored by the Applicant; it should have been limited to the specific meanings given in the description page 8, as otherwise it is difficult to ascertain if the problem has been indeed solved by all the compounds claimed considered as obvious modifications or equivalents to one or more particular examples.

The expression "lower" used in the claims (for many substituents like i.a. alkyl, alkenyl or alkoxy) is considered to be unclear in scope, since it does not precisely define the matter for which protection is sought, specially the upper limit (being in this case sometimes different from group to group).

**Industrial applicability**

For the assessment of the present claims 8 on the question whether it is industrially applicable, no unified criteria exist in the PCT Contracting States. The patentability can also be dependent upon the formulation of the claims. The EPO, for example, does not recognize as industrially applicable the subject-matter of claims to the use of a compound in medical treatment, but may allow, however, claims to a known compound for first use in medical treatment and the use of such a compound for the manufacture of a medicament for a new medical treatment.

## PATENT COOPERATION TREATY

## PCT

## INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference <b>PWO-19119</b>	<b>FOR FURTHER ACTION</b> see Notification of Transmittal of International Search Report (Form PCT/ISA/220) as well as, where applicable, item 5 below.	
International application No. <b>PCT/JP 99/ 06943</b>	International filing date (day/month/year) <b>10/12/1999</b>	(Earliest) Priority Date (day/month/year) <b>14/12/1998</b>
Applicant <b>FUJISAWA PHARMACEUTICAL CO., LTD. et al.</b>		

This International Search Report has been prepared by this International Searching Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the International Bureau.

This International Search Report consists of a total of 3 sheets.

It is also accompanied by a copy of each prior art document cited in this report.

**1. Basis of the report**

a. With regard to the language, the international search was carried out on the basis of the international application in the language in which it was filed, unless otherwise indicated under this item.

the international search was carried out on the basis of a translation of the international application furnished to this Authority (Rule 23.1(b)).

b. With regard to any nucleotide and/or amino acid sequence disclosed in the international application, the international search was carried out on the basis of the sequence listing :

contained in the international application in written form.

filed together with the international application in computer readable form.

furnished subsequently to this Authority in written form.

furnished subsequently to this Authority in computer readable form.

the statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.

the statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished

2.  Certain claims were found unsearchable (See Box I).

3.  Unity of invention is lacking (see Box II).

4. With regard to the title,

the text is approved as submitted by the applicant.

the text has been established by this Authority to read as follows:

5. With regard to the abstract,

the text is approved as submitted by the applicant.

the text has been established, according to Rule 38.2(b), by this Authority as it appears in Box III. The applicant may, within one month from the date of mailing of this international search report, submit comments to this Authority.

6. The figure of the drawings to be published with the abstract is Figure No.

as suggested by the applicant.

because the applicant failed to suggest a figure.

because this figure better characterizes the invention.

None of the figures.

# INTERNATIONAL SEARCH REPORT

International Application No

P 99/06943

**A. CLASSIFICATION OF SUBJECT MATTER**

IPC 7	C07D413/06	C07D401/06	C07D403/06	C07D471/04	C07D413/14
	C07D495/04	C07F7/18	A61K31/535	A61K31/495	A61P29/00
	A61P3/00	A61P27/02	//(C07D413/06, 265:00, 241:00),		

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D C07F

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, X	WO 98 57954 A (NAKAI KAZUO ; TAKE KAZUHIKO (JP); AZAMI HIDENORI (JP); EIKYU YOSHIT) 23 December 1998 (1998-12-23) claims 1-4,6,7,9,10; examples 6,15,16,25 ----	1-3,6,7, 9,10
X	WO 97 22597 A (FUJISAWA PHARMACEUTICAL CO ; MATSUO MASAAKI (JP); MANABE TAKASHI (J) 26 June 1997 (1997-06-26) claims 1-8,10,11,14; examples 24,36,51 ----	1-3,6,7, 9,10
X	WO 97 08166 A (SCHERING CORP) 6 March 1997 (1997-03-06) claims 1-3,5,12-14 ----	1-3,9,10
A	EP 0 655 442 A (FUJISAWA PHARMACEUTICAL CO) 31 May 1995 (1995-05-31) claims 1-3,6-8; table 1 -----	1-3,9,10

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

° Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

8 May 2000

Date of mailing of the international search report

12/05/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Goss, I

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 99/06943

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 (C07D401/06, 241:00, 213:00), (C07D403/06, 241:00, 231:00),  
 (C07D413/14, 265:00, 241:00, 207:00)

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category <sup>o</sup>	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

## \* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
8 May 2000	

Name and mailing address of the ISA  
 European Patent Office, P.B. 5818 Patentlaan 2  
 NL - 2280 HV Rijswijk  
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
 Fax: (+31-70) 340-3016

Authorized officer

Goss, I

**INTERNATIONAL SEARCH REPORT**

Information on patent family members

International Application No

PCT/EP 99/06943

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
WO 9857954	A 23-12-1998	AU 7675098 A		04-01-1999
		EP 0993457 A		19-04-2000
		ZA 9805255 A		06-01-1999
-----	-----	-----	-----	-----
WO 9722597	A 26-06-1997	AU 714931 B		13-01-2000
		AU 1110697 A		14-07-1997
		CA 2240835 A		26-06-1997
		CN 1209125 A		24-02-1999
		EP 0873320 A		28-10-1998
		HU 9901037 A		28-07-1999
-----	-----	-----	-----	-----
WO 9708166	A 06-03-1997	US 5795894 A		18-08-1998
		AU 705683 B		27-05-1999
		AU 5714196 A		21-11-1996
		AU 708834 B		12-08-1999
		AU 6997996 A		19-03-1997
		BR 9608245 A		04-05-1999
		BR 9610277 A		06-07-1999
		CA 2218887 A		07-11-1996
		CA 2228370 A		06-03-1997
		CN 1200120 A		25-11-1998
		CZ 9800228 A		15-07-1998
		CZ 9703423 A		18-03-1998
		EP 0850236 A		01-07-1998
		HU 9801382 A		28-06-1999
		HU 9802552 A		28-10-1999
		JP 10511105 T		27-10-1998
		JP 11504921 T		11-05-1999
		NO 975028 A		30-12-1997
		NO 980848 A		30-04-1998
		NZ 307716 A		28-10-1999
		NZ 318493 A		28-10-1999
		PL 323235 A		16-03-1998
		PL 325339 A		20-07-1998
		SK 27498 A		02-12-1998
		SK 147297 A		08-07-1998
		WO 9634864 A		07-11-1996
		US 5981520 A		09-11-1999
		US 5892039 A		06-04-1999
		EP 0823906 A		18-02-1998
		US 5869488 A		09-02-1999
-----	-----	-----	-----	-----
EP 0655442	A 31-05-1995	AU 689504 B		02-04-1998
		AU 7911194 A		08-06-1995
		CA 2136712 A		30-05-1995
		CN 1107149 A, B		23-08-1995
		HU 71348 A		28-11-1995
		IL 111730 A		06-12-1998
		JP 7242641 A		19-09-1995
		US 5670505 A		23-09-1997
		US 5883098 A		16-03-1999
		ZA 9409228 A		01-08-1995
		BR 9500539 A		31-10-1995
-----	-----	-----	-----	-----

## PARENT COOPERATION TREATY

From the INTERNATIONAL BUREAU

PCT

NOTIFICATION CONCERNING  
SUBMISSION OR TRANSMITTAL  
OF PRIORITY DOCUMENT

(PCT Administrative Instructions, Section 411)

Date of mailing (day/month/year)  
29 February 2000 (29.02.00)To:  
TABUSHI, Eiji  
Fujisawa Pharmaceutical Co., Ltd.  
Osaka Factory  
1-6, Kashima 2-chome  
Yodogawa-ku, Osaki-shi  
Osaka 532-8514  
JAPON

Applicant's or agent's file reference PWO-19119	<b>IMPORTANT NOTIFICATION</b>
International application No. PCT/JP99/06943	International filing date (day/month/year) 10 December 1999 (10.12.99)
International publication date (day/month/year) Not yet published	Priority date (day/month/year) 14 December 1998 (14.12.98)
Applicant FUJISAWA PHARMACEUTICAL CO., LTD. et al	

1. The applicant is hereby notified of the date of receipt (except where the letters "NR" appear in the right-hand column) by the International Bureau of the priority document(s) relating to the earlier application(s) indicated below. Unless otherwise indicated by an asterisk appearing next to a date of receipt, or by the letters "NR", in the right-hand column, the priority document concerned was submitted or transmitted to the International Bureau in compliance with Rule 17.1(a) or (b).
2. This updates and replaces any previously issued notification concerning submission or transmittal of priority documents.
3. An asterisk(\*) appearing next to a date of receipt, in the right-hand column, denotes a priority document submitted or transmitted to the International Bureau but not in compliance with Rule 17.1(a) or (b). In such a case, the attention of the applicant is directed to Rule 17.1(c) which provides that no designated Office may disregard the priority claim concerned before giving the applicant an opportunity, upon entry into the national phase, to furnish the priority document within a time limit which is reasonable under the circumstances.
4. The letters "NR" appearing in the right-hand column denote a priority document which was not received by the International Bureau or which the applicant did not request the receiving Office to prepare and transmit to the International Bureau, as provided by Rule 17.1(a) or (b), respectively. In such a case, the attention of the applicant is directed to Rule 17.1(c) which provides that no designated Office may disregard the priority claim concerned before giving the applicant an opportunity, upon entry into the national phase, to furnish the priority document within a time limit which is reasonable under the circumstances.

<u>Priority date</u>	<u>Priority application No.</u>	<u>Country or regional Office or PCT receiving Office</u>	<u>Date of receipt of priority document</u>
14 Dec 1998 (14.12.98)	PP7706	AU	21 Janu 2000 (21.01.00)
21 Octo 1999 (21.10.99)	PQ3568	AU	21 Janu 2000 (21.01.00)

The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland Facsimile No. (41-22) 740.14.35	Authorized officer Marc Salzman Telephone No. (41-22) 338.83.38
--	---

003136037

## PATENT COOPERATION TREATY

PCT

NOTICE INFORMING THE APPLICANT OF THE  
COMMUNICATION OF THE INTERNATIONAL  
APPLICATION TO THE DESIGNATED OFFICES

(PCT Rule 47.1(c), first sentence)

From the INTERNATIONAL BUREAU

To:

TABUSHI, Eiji  
 Fujisawa Pharmaceutical Co., Ltd.  
 Osaka Factory  
 1-6, Kashima 2-chome  
 Yodogawa-ku, Osaki-shi  
 Osaka 532-8514  
 JAPON

Date of mailing (day/month/year) 22 June 2000 (22.06.00)		IMPORTANT NOTICE	
Applicant's or agent's file reference PWO-19119			
International application No. PCT/JP99/06943	International filing date (day/month/year) 10 December 1999 (10.12.99)	Priority date (day/month/year) 14 December 1998 (14.12.98)	
Applicant FUJISAWA PHARMACEUTICAL CO., LTD. et al			

1. Notice is hereby given that the International Bureau has communicated, as provided in Article 20, the international application to the following designated Offices on the date indicated above as the date of mailing of this Notice:  
AU,CN,JP,KR,US

In accordance with Rule 47.1(c), third sentence, those Offices will accept the present Notice as conclusive evidence that the communication of the international application has duly taken place on the date of mailing indicated above and no copy of the international application is required to be furnished by the applicant to the designated Office(s).

2. The following designated Offices have waived the requirement for such a communication at this time:  
AE,AL,AM,AP,AT,AZ,BA,BB,BG,BR,BY,CA,CH,CU,CZ,DE,DK,EA,EE,EP,ES,FI,GB,GD,GE,GH,GM,  
HR,HU,ID,IL,IN,IS,KE,KG,KZ,LC,LK,LR,LS,LT,LU,LV,MD,MG,MK,MN,MW,MX,NO,NZ,OA,PL,PT,  
RO,RU,SD,SE,SG,SI,SK,SL,TJ,TR,TT,UA,UG,UZ,VN,YU,ZA,ZW

The communication will be made to those Offices only upon their request. Furthermore, those Offices do not require the applicant to furnish a copy of the international application (Rule 49.1(a-bis)).

3. Enclosed with this Notice is a copy of the international application as published by the International Bureau on  
22 June 2000 (22.06.00) under No. WO 00/35915

## REMINDER REGARDING CHAPTER II (Article 31(2)(a) and Rule 54.2)

If the applicant wishes to postpone entry into the national phase until 30 months (or later in some Offices) from the priority date, a demand for international preliminary examination must be filed with the competent International Preliminary Examining Authority before the expiration of 19 months from the priority date.

It is the applicant's sole responsibility to monitor the 19-month time limit.


Note that only an applicant who is a national or resident of a PCT Contracting State which is bound by Chapter II has the right to file a demand for international preliminary examination.

## REMINDER REGARDING ENTRY INTO THE NATIONAL PHASE (Article 22 or 39(1))

If the applicant wishes to proceed with the international application in the national phase, he must, within 20 months or 30 months, or later in some Offices, perform the acts referred to therein before each designated or elected Office.

For further important information on the time limits and acts to be performed for entering the national phase, see the Annex to Form PCT/IB/301 (Notification of Receipt of Record Copy) and Volume II of the PCT Applicant's Guide.

The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland	Authorized officer J. Zahra
Facsimile No. (41-22) 740.14.35	Telephone No. (41-22) 338.83.38



Continuation of Form PCT/IB/308

NOTICE INFORMING THE APPLICANT OF THE COMMUNICATION OF  
THE INTERNATIONAL APPLICATION TO THE DESIGNATED OFFICES

Date of mailing (day/month/year) 22 June 2000 (22.06.00)	<b>IMPORTANT NOTICE</b>
Applicant's or agent's file reference PWO-19119	International application No. PCT/JP99/06943
<p>The applicant is hereby notified that, at the time of establishment of this Notice, the time limit under Rule 46.1 for making amendments under Article 19 has not yet expired and the International Bureau had received neither such amendments nor a declaration that the applicant does not wish to make amendments.</p>	